Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Enterprise Value (2016 - 2025)

Enanta Pharmaceuticals' Enterprise Value history spans 14 years, with the latest figure at -$185.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 118.76% year-over-year to -$185.8 million; the TTM value through Dec 2025 reached -$185.8 million, down 118.76%, while the annual FY2025 figure was -$188.9 million, 23.9% up from the prior year.
  • Enterprise Value reached -$185.8 million in Q4 2025 per ENTA's latest filing, up from -$188.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$60.2 million in Q1 2025 to a low of -$386.6 million in Q2 2023.
  • Average Enterprise Value over 5 years is -$247.0 million, with a median of -$248.7 million recorded in 2022.
  • The largest YoY upside for Enterprise Value was 79.95% in 2025 against a maximum downside of 118.76% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$259.1 million in 2021, then increased by 17.21% to -$214.5 million in 2022, then plummeted by 57.2% to -$337.2 million in 2023, then skyrocketed by 74.8% to -$85.0 million in 2024, then tumbled by 118.76% to -$185.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Enterprise Value are -$185.8 million (Q4 2025), -$188.9 million (Q3 2025), and -$204.1 million (Q2 2025).